Search This Blog

Tuesday, May 5, 2026

Viridian financings to repay Hercules debt and fund TED franchise and pipeline development

 

Viridian Therapeutics launches concurrent note and equity offerings to repay Hercules debt and fund TED franchise and pipeline development

  • $150 million convertible senior notes due 2032 offered in concurrent underwritten financing transaction.
  • $100 million of common and Series B non-voting convertible preferred stock offered concurrently.
  • Positive pivotal Phase 3 REVEAL-1 and REVEAL-2 data support elegrobart in thyroid eye disease, with BLA filing targeted in 2027.
  • First-quarter 2026 results highlight launch readiness ahead of veligrotug's June 30 FDA PDUFA date.
  • Q1 2026 non-GAAP EPS was -$0.90, down 3% YoY, and revenue $141,000, up 96% YoY, both beating estimates.
  • SEC filing shows wider Q1 2026 net loss of $104.9M compared with the prior-year period.

Rhythm beats as early HO launch shows strong traction amid rising spend concerns

 

Rhythm Pharma Q1 2026 revenue $60.1M (+84% YoY) beats estimates as early HO launch shows strong traction amid rising spend concerns

  • Q1 revenue $60.1m, up 84% YoY and 5% QoQ; net loss per share $-0.83, EPS missing estimates.
  • Early U.S. HO launch generated 150+ IMCIVREE start forms in six weeks, including ~40 trial conversions in acquired hypothalamic obesity.
  • Roughly 110 HO prescribers to date, ~80% new to IMCIVREE, indicating broad engagement.
  • International revenue rose 27% QoQ to $23.2m, driven by BBS and HO early-access markets.
  • European HO approval obtained; country launches expected from 2027 after reimbursement and German G-BA processes.
  • Japan HO NDA accepted and under PMDA review; company anticipates approval and launch by end of 2026.
  • BBS base business showed steady prescription growth, temporarily masked by Q1 insurance-transition bridge-drug usage.
  • Non-GAAP 2026 operating expense guidance reiterated at $385–415m, funding HO, Japan, and pipeline.
  • SG&A reached $63.6m, up sharply YoY, reflecting sales force and marketing ramp.
  • Management tone confident but cautious, emphasizing strong HO start yet acknowledging rare-disease launch unpredictability.
  • Main concern: Sustainability of HO demand and payer coverage amid rising spend and rare-disease complexity.
  • Strong quarter, driven by robust early HO launch indicators and expanding international HO footprint.

Usana beats, reiterates guidance

 

Usana Health Sciences reports Q1 2026 EPS $0.61 and revenue $250.0M, beats EPS and revenue estimates, reiterates full-year 2026 guidance

  • Q1 2026 net sales and adjusted EPS both declined year over year.

DaVita beats, raises guidance

 

DaVita beats Q1 2026 estimates with EPS $2.87, revenue $3.416B and raises 2026 earnings outlook on better volume, labor productivity

  • Q1 2026 revenue grew 6% YoY to $3.416B, while non-GAAP EPS increased 44% YoY.
  • Q1 adjusted operating income was $482 million, about $50 million above internal forecast.
  • Q1 adjusted EPS from continuing operations was $2.87; free cash flow was $140 million.
  • Full-year 2026 adjusted operating income guidance raised to $2.15–$2.25 billion, with midpoint up $40 million.
  • Full-year adjusted EPS guidance raised to $14.10–$15.20, driven by higher volume and lower care costs.
  • U.S. treatments per normalized day grew ~40 bps YoY, about 20 bps above expectations.
  • Full-year treatment growth outlook increased from flat to +25–50 bps, including Fresenius clinic closures benefit.
  • Q1 revenue per treatment grew ~4% YoY; full-year RPT growth guidance maintained at 1–2% amid expected mix pressure.
  • ACA enrollment trends slightly better than prior ~$40 million 2026 headwind estimate, but mix and affordability remain uncertain.
  • G&A rose 13% YoY on technology investments, but total cost per treatment CAGR remains ~2.6% over five years.
  • Integrated Kidney Care delivered top CKCC savings and quality scores but still posted a $19 million operating loss.
  • Main concern: Payer mix and ACA dynamics could pressure revenue per treatment and offset operating gains.
  • Strong quarter, driven by better-than-expected treatment volumes, labor productivity, and lower patient care costs.
  • Repurchased 5.0M shares for about $705M through May 5 as part of capital return program.

Supernus beats, affirms guidance, strong performance of Qelbree, GOCOVRI, ZURZUVAE, ONAPGO

 

Supernus Pharmaceuticals Inc reports fiscal Q1 2026 results with non-GAAP EPS $0.60 (+37% YoY) and revenue $207.7M (+39% YoY), beats EPS and revenue estimates

  • Company reported GAAP loss per share of $0.04 for Q1 2026 despite strong revenue growth.
  • Q1 2026 adjusted EPS was $0.59, reflecting improved profitability compared with the prior year.
  • Quarter includes $20M milestone payment from Shionogi, significantly contributing to higher Q1 2026 revenue.
  • Revenue growth was driven by strong performance of Qelbree, GOCOVRI, ZURZUVAE and ONAPGO during the quarter.
  • Company reiterated full-year 2026 guidance, maintaining previously communicated revenue and profitability outlook.

Sun Pharma Explores Funding Mix for $12 Billion Organon Deal

 


Global lenders to Sun Pharmaceutical Industries Ltd. are weighing multiple financing options for its proposed $12 billion acquisition of New York-listed healthcare company Organon & Co., according to people familiar with the matter.

The Indian drugmaker is considering seeking consent from Organon bondholders to swap their holdings into Sun Pharma debt, the people said, asking not to be identified discussing private matters. It is also working on a potential euro-denominated bond that could carry a credit rating one to two notches higher than the one assigned to Organon before the proposed merger, they added.

https://www.bloomberg.com/news/articles/2026-05-06/sun-pharma-explores-funding-mix-for-12-billion-organon-deal

The Golden State Has Fallen: Welcome To The Islamic Republic Of California

 by Rabbi Michael Barclay via American Greatness,

On April 8, the California Assembly Committee on Public Employment and Retirement voted 19–0 to adopt AB2017, followed on April 22 by the California Assembly Committee on Appropriations, which voted 7–0 to adopt the bill. And with those votes, all that is left for this to become California law is the passing of it by the State Assembly and Senate and approval by the governor.

And with it, the state of California will no longer exist as we know it, but will become the Islamic Republic of California.

Introduced by California Assemblyman Matt Haney (D-San Francisco 17th District) at the behest of CAIR, the bill seeks to officially recognize the Islamic holidays of Eid al-Fitr and Eid al-Adha as California state holidays.

There are no holidays from other religions that are recognized as state holidays in California.

Rosh Hashanah, Yom Kippur, Ash Wednesday, Good Friday, and Epiphany are all extremely important holidays in Judaism and Christianity.

But none of them are recognized as California state holidays.

But according to Haney and the California legislature, apparently, Islamic holidays are much more important to the state than either Judaism or Christianity.

This bill is clearly unconstitutional, as it is in direct contradiction to the Establishment Clause of the First Amendment: “Congress shall make no law respecting an establishment of religion or prohibiting the free exercise thereof . . .”

By placing two Islamic holidays as official state holidays, they are respecting the establishment of a specific religion. But the problem is greater than just their violation of the Constitution in attempting to pass this bill.

The holidays themselves, Eid al-Fitr and Eid al-Adha, are expressions and manifestations of the very worst aspects of Islam.

Eid al-Fitr marks the end of the Islamic month of Ramadan and is the penultimate celebration of the month and its meanings. Ramadan is the month-long holiday commemorating Mohammed’s first vision in 610 CE, in which he supposedly was visited by the angel Gabriel (named Jibril in Arabic) in a cave near Mecca and given a revelation that ultimately became the Quran. It is a month of fasting and a national holiday in countries such as Iran, Turkey, the UAE, Saudi Arabia, and other Muslim theocracies.

It is also traditionally the month of war in Islam. Although war is forbidden in the Quran during four other months (the 1st, 7th, 11th, and 12th), it is not only allowed during Ramadan; it has historically been encouraged to be a month of initiating war against “infidels.” The Yom Kippur War against Israel in 1973 was started by the Arabs during Ramadan. Three years ago, Ismail Haniyeh, who was considered the political leader of Hamas (and who lived in Qatar until killed in July of 2024 and had a net worth of over two billion dollars), called for all Arabs to attack Israel during Ramadan and to siege and blockade the Al-Aqsa Mosque in Jerusalem and have continual mass riots there. Ramadan, going back to Mohammed himself, is the time to start wars on non-Muslims and is a source of Islamic pride as the time to forcefully convert the world to Islam. The Nusra Front, al-Qaeda’s official arm in Syria, has even described Ramadan as “a month of conquests.

Some historical examples of the Islamic intention during Ramadan include the Battle of Badr, a victory led by Mohammed himself in the second Ramadan; the conquest of Mecca, 6 years after Badr; the war for Andalusia in 711 CE; the Battle of Ain Jalut against the Mongols; and the Battle of Hattin during the Crusades.

And that’s just in the first 200 years of Islamic history.

But Matt Haney and the California Legislature want to make this holiday, which is about military victory over non-Muslims, into an official state holiday!

And then there is the second Islamic holiday that they want to make an official state holiday: Eid al-Adha, the “Feast of the Sacrifice.” This is a holiday about being willing to violently sacrifice and kill if it is commanded by Allah. It includes throwing stones at a wall to symbolize the willingness to fight for the “will of God” by stoning Satan and exemplifies the observant Islamic belief in stoning when “required.” Animals are also sacrificed as part of this holiday’s celebration. And this is not a small sacrifice of one chicken for an entire community, but rather, the expectation is that each Muslim will perform animal sacrifices.

In Bangladesh, 13 million animals are sacrificed each year; in Pakistan, more than nine million; and globally, it is estimated that approximately 50 million animals are sacrificed each year for this Islamic holiday.

Each year, this holiday causes the death of 50 million animals and encourages the practice of stoning anything that is contradictory to the Quran, Hadith, and Islamic theology. And this is the holiday that Haney and his Democratic colleagues in the California State Legislature want to make into an official state holiday.

War, stoning, and animal sacrifice—these are the values that have been unanimously approved by the committee, and are on track to becoming approved by the California government.

Yom Kippur is a Jewish holiday about the value of being self-reflective and atoning for our personal sins. Epiphany is a Christian holiday celebrating the baptism of Jesus; Good Friday deepens the Christian faith as it honors the sacrifice of Jesus on the cross for all of humanity; and Ash Wednesday reminds Christians of the journey of Jesus during Lent that leads to the Resurrection on Easter. Atonement, spiritual awareness, faith in God: these are values that the State of California rejects as holidays while honoring the Islamic values of war and death.

With the passing of this bill, which is not certain but is highly likely, California will officially have gone off the cliff, rejecting Western civilization in favor of officially adopting Islamic practices and values.

Rest in peace, California. We will miss you.

https://www.zerohedge.com/political/golden-state-has-fallen-welcome-islamic-republic-california